Phase I study of tirabrutinib (ONO‐4059/GS‐4059) in patients with relapsed or refractory B‐cell malignancies in Japan

We evaluated the safety, efficacy, pharmacokinetics, pharmacodynamics and predictive biomarkers of tirabrutinib, a second‐generation, enhanced‐selectivity Bruton's tyrosine kinase inhibitor in Japanese patients with relapsed/refractory B‐cell non−Hodgkin lymphoma (B‐cell NHL) and chronic lympho...

Descripción completa

Detalles Bibliográficos
Autores principales: Munakata, Wataru, Ando, Kiyoshi, Hatake, Kiyohiko, Fukuhara, Noriko, Kinoshita, Tomohiro, Fukuhara, Suguru, Shirasugi, Yukari, Yokoyama, Masahiro, Ichikawa, Satoshi, Ohmachi, Ken, Gion, Naokazu, Aoi, Arata, Tobinai, Kensei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500982/
https://www.ncbi.nlm.nih.gov/pubmed/30815927
http://dx.doi.org/10.1111/cas.13983

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500982/
https://www.ncbi.nlm.nih.gov/pubmed/30815927
http://dx.doi.org/10.1111/cas.13983

Ejemplares similares